Osteoporosis and sarcopenia · 2025
Sarcopenia and sarcopenic obesity in rheumatoid arthritis patients: prevalence and their relationship with joint damage and functional impairment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guzmán-Guzmán Iris Paola, Villafan-Bernal José Rafael, Gutiérrez-Pérez Ilse Adriana, Falfán-Valencia Ramcés, Rojas-Delgado Héctor Ugo, Alarcón-Paredes Antonio, Villaquiran-Hurtado Andrés Felipe, Alonso-Silverio Gustavo Adolfo, Zaragoza-García Oscar
Аннотация
OBJECTIVES: Sarcopenia and sarcopenic obesity are associated with a depletion of muscle mass, strength, and performance in rheumatoid arthritis (RA). We aimed to determine the prevalence of sarcopenia and sarcopenic obesity, as well as the clinical factors.
METHODS: A cross-sectional study was carried out with 262 patients suffering from RA (230 women and 32 men). Demographic data, anthropometric measurements, clinical features, and previous medication were recorded. Sarcopenia was defined based on the 2019 consensus of the Asian Working Group for Sarcopenia. The combination of sarcopenia and an excess of body fat mass was classified as sarcopenic obesity. Multivariable-adjusted regression analysis was used to explore potential factors associated with sarcopenia phenotypes in RA patients.
RESULTS: Among the study participants, 49.6% had sarcopenia; of those, 66.9% had sarcopenic obesity. Subjects with sarcopenia were significantly older, had a longer duration of illness, more morning stiffness, higher radiological grade, and elevated erythrocyte sedimentation rate levels. Additionally, female sex and the use of combinations of disease-modifying antirheumatic drugs were significantly more common in the sarcopenia group compared to patients without sarcopenia (all P < 0.05).
CONCLUSIONS: The prevalence of sarcopenia and sarcopenic obesity is high among Mexican patients with RA, and the current study shows that sarcopenia phenotypes are linked to worse functional impairment and significantly higher joint damage score. Early detection, nutritional intervention, and treatment of muscle dysfunction could enhance the quality of life and outcomes for RA patients.
METHODS: A cross-sectional study was carried out with 262 patients suffering from RA (230 women and 32 men). Demographic data, anthropometric measurements, clinical features, and previous medication were recorded. Sarcopenia was defined based on the 2019 consensus of the Asian Working Group for Sarcopenia. The combination of sarcopenia and an excess of body fat mass was classified as sarcopenic obesity. Multivariable-adjusted regression analysis was used to explore potential factors associated with sarcopenia phenotypes in RA patients.
RESULTS: Among the study participants, 49.6% had sarcopenia; of those, 66.9% had sarcopenic obesity. Subjects with sarcopenia were significantly older, had a longer duration of illness, more morning stiffness, higher radiological grade, and elevated erythrocyte sedimentation rate levels. Additionally, female sex and the use of combinations of disease-modifying antirheumatic drugs were significantly more common in the sarcopenia group compared to patients without sarcopenia (all P < 0.05).
CONCLUSIONS: The prevalence of sarcopenia and sarcopenic obesity is high among Mexican patients with RA, and the current study shows that sarcopenia phenotypes are linked to worse functional impairment and significantly higher joint damage score. Early detection, nutritional intervention, and treatment of muscle dysfunction could enhance the quality of life and outcomes for RA patients.